PO.ET01.03 · 实验与分子治疗
Next-Generation Targeted Therapies Directed Against Tumor Surface Antigens
- 4533 4533 利用Oncolinkage平台鉴定的新型高选择性实体瘤靶点的CAR的发现与表征 Discovery and characterization of CARs against novel, highly selective solid tumor targets identified using the Oncolinkage platform McKensie Collins, Benjamin Hallisey, Andrew Astley, Murray O. Robinson
-
-
-
-
- 4539 4539 一种靶向MUC1-C的ADC在完整和睾酮耗竭的临床前模型中均对神经内分泌前列腺癌表现出强效抗肿瘤活性 A MUC1-C-targeting ADC exhibits potent antitumor activity against neuroendocrine prostate cancer in both intact and testosterone-depleted preclinical models Surender Kharbanda, Rehan Ahmad, Deepak Raina, Changchuin Mao, Sourav Choudhary, Brian Lawney, Nandita Sreenivasalu, Govind Panchamoorthy, Neeraj Agarwal, Ravi Jasuja
- 4540 4540 BC602:一种处于IND申报支持阶段的LGR5x EGFR双特异性抗体,在小鼠CDX和PDX模型中具有卓越的抗肿瘤疗效 BC602: An IND-enabling stage LGR5x EGFR bispecific antibody with superior anti-tumor efficacy in mouse CDX and PDX models Zhe Shao, Tao Wang, Wen Chao Jia, Keng Hoe Lok, Zhong Zong Pan
-
-
- 4543 4543 一种新型 CDH17 靶向放射性配体疗法可克服对微管抑制剂和拓扑异构酶 I 抑制剂 ADC 的耐药，并在胃肠道肿瘤中实现强效疗效 A novel CDH17-targeted radioligand therapy overcomes resistance to microtubule and topoisomerase I inhibitor ADCs and achieves potent efficacy in GI-tract tumors Abdul Mondal, Garima Kaushik, Marina Bell, Maxwell Hilbert, Arnab Mukharjee, Dennis Beckford, Paul Heverly, Michael Ritchie, Kakajan Komurov
- 4544 4544 预测性生物标志物及联合策略：克服 SCLC 中对携带拓扑异构酶 I 抑制剂载荷的 HER2 和 TROP2 靶向抗体药物偶联物的耐药 Predictive biomarkers and combination strategies to overcome resistance to HER2- and TROP2-directed antibody drug conjugates with topoisomerase I inhibitor payloads in SCLC Kavya Ramkumar, C. Allison Stewart, Shui-Ping So, Runsheng Wang, Azusa Tanimoto, Alberto Duarte Jr., Jenna H. Gray, Li Shen, Lixia Diao, Yuanxin Xi, Qi Wang, Alejandra G. Serrano, Luisa M. Solis Soto, Jing Wang, Bingnan Zhang, Carl M. Gay, Lauren A. Byers
-
- 4546 4546 HER2 和 TROP2 抗体药物偶联物在小细胞肺癌细胞系及 3D 培养中的应用：疗效及靶点表达的作用 HER2- and TROP2-antibody-drug conjugates in small cell lung cancer cell lines and 3D culture: Efficacy and role of target expression Jenna Gray, Kavya Ramkumar, C. Allison Stewart, Runsheng Wang, Alberto Duarte, Azusa Tanimoto, Robert J. Cardnell, Lauren Averett Byers, Carl M. Gay
- 4547 4547 TRO-02：一种整合 TROCAD™ 和 TROSIG™ 平台的条件激活型 EGFR 靶向 ADC，显示出增强的肿瘤选择性和强效疗效 TRO-02, a conditionally activated EGFR-targeting ADC incorporating TROCAD TM and TROSIG TM platforms, shows enhanced tumor selectivity and potent efficacy Young Hun Lee, Do Hyeon Kim, Eun Young Shim, Eunhyun Choi, Jong Un Cho, Myoungki Baek, Sung Ho Woo
- 4548 4548 利用抗体药物偶联物靶向 B7-H6 治疗弥漫性大 B 细胞淋巴瘤 Therapeutically targeting B7-H6 with antibody-drug conjugates for diffuse large B-cell lymphoma Qiaoling Ye, Ye Lu, Chulin Sha, Peng Guo
- 4549 4549 HMPL-A580 的发现：一种首创的抗体靶向治疗偶联物（ATTC），由一种新型 PI3K/PIKK 抑制剂载荷连接至抗 EGFR 抗体构成 Discovery of HMPL-A580, a first-in-class antibody-targeted therapy conjugate (ATTC) of a novel PI3K/PIKK inhibitor payload linked to an anti-EGFR antibody Yu Cai, Xiangling Chen, Shishuang Chen, Na Yang, Yan Xu, Huijing Yu, Shiming Fan, Haibin Yang, Min Cheng, Nelson Ng, Jianlin He, Shaohui Shen, Weigang He, wei shao, xiaoming dai, Yajing Bai, Yizhen Yang, linfang wang, Jian Wang, Weihan Zhang, Yongxin Ren, Guangxiu Dai, Michael Shi, Weiguo Su
-
-
- 4552 4552 BSI-730，一种首创的HER2xPD-L1双特异性ADC，通过选择性杀伤肿瘤细胞和免疫调节在HER2低表达模型中展现出强效抗肿瘤活性 BSI-730, a first-in-class HER2xPD-L1 bi-specific ADC, demonstrates potent anti-tumor activity in HER2-low models via selective tumor cell killing and immune modulation Hui-Han Hu, Xiaoyao Hao, Yue Gao, Hongyan Li, Jinyu Liu, Jinge Zhao, Yi Lu, Liezhou Ji, Zhigang Ma, Mingjiu Chen, Kedan Lin
- 4553 4553 BSI-128（AK2024）增强trastuzumab功能并在HER2阳性临床前模型中增效trastuzumab-deruxtecan的活性 BSI-128 (AK2024) enhances trastuzumab function and potentiates trastuzumab-deruxtecan activity across HER2-positive preclinical models Hui-Han Hu, Yinghui Dou, Hongyan Li, Liansheng Cheng, Jinyu Liu, Li Wei, Wenwen Dai, Daoqin Liu, Hui Wang, Ting Xu, Xiaoyao Hao, Yue Gao, Jinge Zhao, Yi Lu, Mingjiu Chen, Kedan Lin
-
